Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CABG Beats DES In SYNTAX Trial; Observers Expect Little Change In Practice

This article was originally published in The Gray Sheet

Executive Summary

Analysts and physicians predict one-year results from the SYNTAX trial will have little short-term impact on demand for drug-eluting stents, even though the devices performed worse than coronary artery bypass graft (CABG) surgery in this seminal randomized trial

You may also be interested in...



Large ASCERT Observational Study Favors CABG Over PCI

Bypass graft surgery had a relative risk reduction of about 20% long term compared to stenting.

PCI Versus CABG: Comparative Effectiveness Study Funded By ARRA Grant

The American College of Cardiology and Society of Thoracic Surgeons will study the comparative effectiveness of percutaneous coronary intervention and coronary artery bypass graft surgery with a $4 million NIH research grant, announced Oct. 2

PCI Versus CABG: Comparative Effectiveness Study Funded By ARRA Grant

The American College of Cardiology and Society of Thoracic Surgeons will study the comparative effectiveness of percutaneous coronary intervention and coronary artery bypass graft surgery with a $4 million NIH research grant, announced Oct. 2

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel